Estimated Cancer Risk in Females Who Meet the Criteria to Exit Cervical Cancer Screening
Open Access
- 3 March 2025
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (3) , e250479
Abstract
Importance: Cervical screening guidelines in the US recommend that most females can exit routine screening at age 65 years following 2 recent consecutive negative cotest results (concurrent human papillomavirus and cytology tests). However, empirical data on the subsequent risks of cancer and cancer death in this subgroup of females are limited.Objective: To estimate the risks of cervical cancer and cervical cancer death among females who meet the cotesting criteria to exit screening.Design, Setting, and Participants: In this decision analytical comparative modeling study, 4 decision analytical models from the Cancer Intervention and Surveillance Modeling Network–Cervical modeling consortium that fit common US epidemiological data targets were validated against published estimates of 3- and 5-year risks of cervical intraepithelial neoplasia grade 3 (CIN3) among females meeting exit criteria at Kaiser Permanente Northern California (KPNC).Main Outcomes and Measures: Age-conditional and cumulative risks of cervical cancer and cervical cancer death at ages 65, 70, 75, 80, and 85 years were estimated by performing a comparative modeling analysis of the 4 models to estimate the risks of cervical cancer and cervical cancer death after exiting screening.Results: All models estimated a 5-year risk of CIN3 that was within the range of empirical data from KPNC. Projections of the cumulative and age-conditional risks of cervical cancer and cervical cancer death increased with time since exiting screening. The cumulative risks of cervical cancer and cervical cancer death by age 70 years were estimated to range from 0.001% to 0.003% and from 0% to 0.001%, respectively. The cumulative risks of cervical cancer and cervical cancer death by age 85 years ranged from 0.026% to 0.081% and from 0.005% to 0.038%, respectively, across models. Results were sensitive to assumptions about screening test sensitivity and incidence of high-risk human papillomavirus.Conclusions and Relevance: In this decision analytical comparative modeling study, a low risk of cervical cancer and cervical cancer death was estimated among females who fulfilled the US criteria to exit screening with cotesting; however, the risks increased with age and/or time since screening exit. The findings suggest that future guidelines should consider acceptable risk levels when defining screening modality and exit age requirements.Keywords
This publication has 23 references indexed in Scilit:
- How confident can we be in the current guidelines for exiting cervical screening?Preventive Medicine, 2018
- Screening for Cervical Cancer in Primary CareJAMA, 2018
- Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical CancerAnnals of Internal Medicine, 2018
- Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysisThe Lancet Oncology, 2017
- Modeling of US Human Papillomavirus (HPV) Seroprevalence by Age and Sexual Behavior Indicates an Increasing Trend of HPV Infection Following the Sexual RevolutionThe Journal of Infectious Diseases, 2017
- Human papillomavirus testing 2007–2012: Co‐testing and triage utilization and impact on subsequent clinical managementInternational Journal of Cancer, 2014
- Cervical excisional treatment of young women: A population-based studyGynecologic Oncology, 2014
- Cervical Screening at Age 50–64 Years and the Risk of Cervical Cancer at Age 65 Years and Older: Population-Based Case Control StudyPLOS Medicine, 2014
- Screening for Cervical CancerJournal of Lower Genital Tract Disease, 2013
- American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical CancerAmerican Journal of Clinical Pathology, 2012